What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

The goal was to compare the efficacy of teclistamab plus daratumumab in multiple myeloma patients.

December 9, 2025

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Puntos clave

The goal was to compare the efficacy of teclistamab plus daratumumab in multiple myeloma patients.
Patients received teclistamab plus daratumumab regimen compared to DPd or DVd groups.
Participants had one to three previous lines of therapy.
The teclistamab-daratumumab group had significantly longer progression-free survival than those in DPd or DVd group.

Resumen

In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson ClinicalTrials.gov number, NCT05083169.).

Me gusta

Guardar